{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:01:58Z","timestamp":1790204518694,"version":"4.1.0"},"reference-count":66,"publisher":"Impact Journals, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,2,16]]},"DOI":"10.18632\/oncotarget.6531","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T02:37:53Z","timestamp":1449715073000},"page":"7597-7609","source":"Crossref","is-referenced-by-count":38,"title":["90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity"],"prefix":"10.18632","volume":"7","author":[{"given":"Patrizia","family":"Mondello","sequence":"first","affiliation":[{"name":"Department of Human Pathology, University of Messina, Messina, Italy"},{"name":"Department of Biological and Environmental Sciences, University of Messina, Messina, Italy"},{"name":"Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[{"name":"Department of Biological and Environmental Sciences, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Navarra","sequence":"additional","affiliation":[{"name":"Department of Biological and Environmental Sciences, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital S. Maurizio, Bolzano\/Bozen, Italy"},{"name":"Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors","volume":"327","author":"Levy","year":"1992","journal-title":"N Engl J Med"},{"key":"2","first-page":"427","article-title":"Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma","volume":"2","author":"Schlossman","year":"1984","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"Lister","year":"1998","journal-title":"J Clin Oncol"},{"key":"4","first-page":"1462","article-title":"Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication","volume":"62","author":"Hammerling","year":"2002","journal-title":"Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-011-9281-4","article-title":"Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy","volume":"30","author":"Fridman","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","article-title":"Monoclonal antibody-based therapies of leukemia and lymphoma","volume":"80","author":"Nadler","year":"1992","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"White","year":"2002","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"9","first-page":"8048","article-title":"Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: meta-analysis of five clinical trials and 9 years of post-approval safety data","volume":"29","author":"Tidmarsh","year":"2011","journal-title":"J Clin Oncol"},{"key":"10","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y labeled anti-CD20 monoclonal antibody","volume":"43","author":"Conti","year":"2002","journal-title":"J Nucl Med"},{"key":"11","first-page":"1017","article-title":"Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non- Hodgkin's lymphoma","volume":"15","author":"Anderson","year":"1999","journal-title":"Int J Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.1992.10.11.1696","article-title":"Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma","volume":"10","author":"Miller","year":"1992","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"13","first-page":"286","article-title":"Patterns of presentation and relapse in the non-Hodgkin's lymphomata","author":"Kaplan","year":"1975","journal-title":"Br J Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hon.989","article-title":"Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms","volume":"29","author":"Ladetto","year":"2011","journal-title":"Hematol Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Zinzani","year":"2008","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Greco","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"17","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Luong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"18","first-page":"99","article-title":"Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma","volume":"118","author":"McLaughlin","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"19","first-page":"3946","article-title":"Update on a prospective study evaluating the safety and efficacy of combination therapy with fludarabine, mitoxantrone andC rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front line therapy for patients with indolent lymphomas","volume":"116","author":"Gregory","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdr145","article-title":"A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate\/high-risk follicular lymphoma","volume":"23","author":"Scopinaro","year":"2012","journal-title":"Ann Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Pedersen","year":"2011","journal-title":"Lancet"},{"key":"22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma","volume":"18","author":"Flowers","year":"2015","journal-title":"Value Health"},{"key":"23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Frericks","year":"2013","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Stelitano","year":"2013","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"D\u00fcrk","year":"2013","journal-title":"Lancet"},{"key":"26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","article-title":"Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF\/BNLI criteria","volume":"32","author":"Bardies","year":"2014","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"White","year":"2002","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","article-title":"Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma","volume":"5","author":"White","year":"2004","journal-title":"Clin Lymphoma"},{"key":"29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma","volume":"47","author":"Molina","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdm560","article-title":"A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients","volume":"19","author":"de Vivo","year":"2008","journal-title":"Ann Oncol"},{"key":"31","first-page":"1793","article-title":"Final results of a phase II study of sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL)","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"32","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1158\/1078-0432.CCR-10-0162","article-title":"Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients","volume":"16","author":"Gandolfi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Gisselbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.13493","article-title":"A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I\/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402","volume":"170","author":"Horning","year":"2015","journal-title":"Br J Haematol"},{"key":"35","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Southwest Oncology Group Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Miller","year":"2008","journal-title":"J Clin Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Fisher","year":"1998","journal-title":"N Engl J Med"},{"key":"37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation","volume":"110","author":"Marcus","year":"2007","journal-title":"Blood"},{"key":"38","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Wiseman","year":"2007","journal-title":"Cancer"},{"issue":"suppl 15","key":"39","first-page":"8558","article-title":"Long-term survival with 90yttrium ibritumomab tiuxetan and rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma","author":"Joyce","year":"2013","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"40","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.27418","article-title":"A randomized study comparing yttrium-90 ibritumomabtiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma","volume":"118","author":"Nagler","year":"2012","journal-title":"Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.bbmt.2014.07.028","article-title":"Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen","volume":"20","author":"Krishnan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"42","first-page":"5121","article-title":"90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-\/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment","volume":"34","author":"Mian","year":"2014","journal-title":"Anticancer Res"},{"key":"43","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/cam4.247","article-title":"Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis","volume":"3","author":"Quittet","year":"2014","journal-title":"Cancer Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progressionfree survival","volume":"20","author":"Shipp","year":"2002","journal-title":"J Clin Oncol"},{"key":"45","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Aldaoud","year":"2005","journal-title":"J Clin Oncol"},{"key":"46","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Younes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"47","first-page":"7560","article-title":"Sequential radioimmunotherapy with tositumomab\/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions","volume":"24","author":"Divgi","year":"2006","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"48","first-page":"3119","article-title":"Phase II study of R-CHOP and 90Y-ibritumomab tiuxetan in patients with previously untreated mantle celllymphoma (E1499)","volume":"30","author":"Horning","year":"2012","journal-title":"J Clin Oncol"},{"key":"49","first-page":"439","article-title":"R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: Outcome of the first randomized trial for elderly patients with mantle cell lymphoma","volume":"118","author":"Kanz","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"50","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Wisconsin Oncology NetworkMaintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network","volume":"17","author":"Bailey","year":"2006","journal-title":"Ann Oncol"},{"key":"51","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progressionfree survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Aldaoud","year":"2005","journal-title":"Blood"},{"key":"52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s10637-009-9283-z","article-title":"Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"28","author":"Suh","year":"2010","journal-title":"Invest New Drugs"},{"key":"53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma","volume":"26","author":"Forman","year":"2008","journal-title":"J Clin Oncol"},{"key":"54","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Kogut","year":"2005","journal-title":"Blood"},{"key":"55","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","article-title":"Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"27","author":"Singhal","year":"2009","journal-title":"J Clin Oncol"},{"key":"56","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Nilsson-Ehle","year":"2014","journal-title":"Blood"},{"key":"57","article-title":"Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma","author":"Pabst","year":"2015","journal-title":"Hematol Oncol"},{"key":"58","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Ji","year":"2009","journal-title":"J Clin Oncol"},{"key":"59","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study","volume":"92","author":"Reyes","year":"1998","journal-title":"Blood"},{"key":"60","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Shi","year":"2006","journal-title":"J Clin Oncol"},{"key":"61","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Kaufmann","year":"2005","journal-title":"J Clin Oncol"},{"key":"62","first-page":"4786","article-title":"Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin(R)) in patients with relapsed or refractory mantle cell lymphoma (MCL) after\/not appropriate for autologous stem cell transplantation (ASCT) - A phase II trial of the European MCL Network","volume":"106","author":"Dreyling","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ijc.1040","article-title":"Protease inhibitors restore radiationinduced apoptosis to Bcl-2-expressing lymphoma cells","volume":"96","author":"Meyn","year":"2001","journal-title":"Int J Cancer"},{"key":"64","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/bjc.1998.183","article-title":"The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF- alphainitiated apoptosis","volume":"77","author":"Magdel\u00e9nat","year":"1998","journal-title":"Br J Cancer"},{"key":"65","first-page":"2406","article-title":"Active combination therapy of bortezomib and ibritumomab tiuxetan in an in vivo diff use large B-cell lymphoma model","volume":"106","author":"de Vos","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"66","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/10428194.2011.608445","article-title":"A phase I study evaluating ibritumomab tiuxetan (Zevalin\u00ae) in combination with bortezomib (Velcade\u00ae) in relapsed\/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma","volume":"53","author":"Goy","year":"2012","journal-title":"Leuk Lymphoma"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T17:14:00Z","timestamp":1589217240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,2,16]]}},"alternative-id":["6531","26657116"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6531","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]}}}